Clinical Trial Update: A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma [Phase 2]

View source ↗

Summary

Phase II study evaluating the mTOR inhibitor everolimus (RAD001) in Kaposi sarcoma has been terminated; the trial explored molecular pharmacodynamic endpoints.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma

Drugs mentioned

• Afinitor (everolimus) (everolimus)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Kaposi Sarcoma | Phase 2 | Status: TERMINATED